Latest Oncothyreon Inc. Stories
SEATTLE, WA, Sept. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Rodman Renshaw 11th Annual Healthcare Conference taking place Sept. 9-11, 2009 in New York. Dr. Kirkman will present at 2 p.m. Eastern Time on Thursday, Sept. 10. A live and archived webcast of the presentation will be accessible at http://www.wsw.com/webcast/rrshq15/onty or by visiting the...
SEATTLE, Aug. 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) today reported a net loss of $6.3 million, or $0.30 per basic and diluted share, for the three months ended June 30, 2009, compared with a net loss of $4.9 million, or $0.25 per basic and diluted share, for the comparable period in 2008. Oncothyreon recorded a non-cash charge of $2.5 million in the three months ended June 30, 2009 for the change in the fair value of warrants issued in connection with its...
SEATTLE, Aug. 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 million on August 7, 2009. Oncothyreon sold the shares and warrants for $6.5775 per unit (each unit consisting of one share and a warrant to purchase 0.30 shares of common...
SEATTLE, Aug. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial results on Wednesday, August 12, 2009 after the close of the U.S. and Canadian markets. Following the release, Oncothyreon's management expects to discuss these financial results and give a general...
SEATTLE, Aug. 4 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it has obtained commitments from several investors to purchase approximately 2.28 million shares of its common stock and warrants to purchase approximately 684,000 shares of its common stock for gross proceeds of approximately $15.0 million. The investors have agreed to purchase the shares and warrants for $6.5775 per unit (each unit consisting of one share and a warrant to purchase 0.30...
SEATTLE, WA, Aug. 4 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Diana Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. In this position, Dr. Hausman will be responsible for planning and implementing the clinical development program for the Company's pipeline of oncology product candidates. "Dr. Hausman is an experienced oncologist who brings an extensive background in drug development to her new...
SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer in San Francisco on August 1, 2009. The presentation by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre, Ottawa, Ontario, involved 16 patients who received treatment with Stimuvax for...
PENNS PARK, Pa., June 22, /PRNewswire/ -- The following is an investment opinion release issued byMicrocapUnderground.com. theMicrocapUnderground.com announces availability of stock alerts on today's active stocks. Stock alerts highlight recent news, trading activity and relevant market research. Investors can view all of the stock alerts for free by visiting www.TheMicrocapUnderground.com. Today's stock Alert focused on: Oncothyreon, Inc. (Nasdaq: ONTY). TheMicroCapunderground.com...
SEATTLE, June 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon. The Phase 3 trial,...
SEATTLE, June 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and Development at Oncothyreon. In this position, Dr. Peterson will be responsible for overseeing those pre-clinical and non-clinical research and development activities that will support the advancement of the Company's pipeline of oncology product candidates into late phase clinical trials. "Scott brings...
